Myotonic Dystrophy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Myotonic Dystrophy - Pipeline Review, H2 2016

Myotonic Dystrophy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Myotonic Dystrophy - Pipeline Review, H2 2016
Published Jul 20, 2016
60 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Myotonic Dystrophy - Pipeline Review, H2 2016, provides an overview of the Myotonic Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myotonic Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myotonic Dystrophy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myotonic Dystrophy
- The report reviews pipeline therapeutics for Myotonic Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Myotonic Dystrophy therapeutics and enlists all their major and minor projects
- The report assesses Myotonic Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myotonic Dystrophy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Myotonic Dystrophy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myotonic Dystrophy pipeline depth and focus of In

  
Source:
Document ID
GMDHC8295IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Myotonic Dystrophy Overview81
Therapeutics Development92
  Pipeline Products for Myotonic Dystrophy Overview91
  Pipeline Products for Myotonic Dystrophy Comparative Analysis101
Myotonic Dystrophy Therapeutics under Development by Companies111
Myotonic Dystrophy Therapeutics under Investigation by Universities/Institutes121
Myotonic Dystrophy Pipeline Products Glance132
  Clinical Stage Products131
  Early Stage Products141
Myotonic Dystrophy Products under Development by Companies151
Myotonic Dystrophy Products under Investigation by Universities/Institutes161
Myotonic Dystrophy Companies Involved in Therapeutics Development177
  AMO Pharma Limited171
  BioMarin Pharmaceutical Inc.181
  F. Hoffmann-La Roche Ltd.191
  Ionis Pharmaceuticals, Inc.201
  Marina Biotech, Inc.211
  Sarepta Therapeutics, Inc.221
  WAVE Life Sciences Ltd.231
Myotonic Dystrophy Therapeutics Assessment249
  Assessment by Monotherapy Products241
  Assessment by Target252
  Assessment by Mechanism of Action272
  Assessment by Route of Administration292
  Assessment by Molecule Type312
Drug Profiles3322
  Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy Drug Profile331
  Antisense RNAi Oligonucleotides for Myotonic Dystrophy Drug Profile341
  IONISDMPK-2.5Rx Drug Profile351
  IUCT-169 Drug Profile361
  IUCT-290 Drug Profile371
  IUCT-309 Drug Profile381
  LR-08 Drug Profile391
  mexiletine hydrochloride Drug Profile401
  Oligonucleotide 1 to Target Dystrophia Myotonica Protein Kinase for Myotonic Dystrophy Drug Profile411
  Oligonucleotides to Inhibit DM1 Protein Kinase for Myotonic Dystrophy Drug Profile421
  PRO-135 Drug Profile431
  RP-33 Drug Profile441
  Small Molecule to Target CUG RNA for Myotonic Dystrophy 1 Drug Profile451
  Small Molecule to Target RNA for Myotonic Dystrophy Drug Profile461
  Small Molecules for Myotonic Dystrophy Drug Profile471
  Small Molecules for Myotonic Dystrophy Type 1 Drug Profile481
  Small Molecules to Inhibit MBNL1 for Myotonic Dystrophy Type I Drug Profile491
  Small Molecules to Target RNA for Myotonic Dystrophy Drug Profile501
  SRT-149 Drug Profile511
  SRT-152 Drug Profile521
  tideglusib Drug Profile531
  VAL-0411 Drug Profile541
Myotonic Dystrophy Dormant Projects551
Myotonic Dystrophy Discontinued Products561
Myotonic Dystrophy Product Development Milestones572
  Featured News &Press Releases571
    Sep 19, 2013: AmorChem invests in the development of a therapeutic to treat myotonic dystrophy571
    Dec 20, 2012: Scripps Florida Scientists Create New Approach to Destroy Disease-Associated RNAs in Cells572
Appendix592
  Methodology591
  Coverage591
  Secondary Research591
  Primary Research591
  Expert Panel Validation591
  Contact Us591
  Disclaimer601

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Myotonic Dystrophy - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Myotonic-Dystrophy-Pipeline-Review-H2-2016-2088-16258>
  
APA:
Global Markets Direct - Market Research. (2016). Myotonic Dystrophy - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Myotonic-Dystrophy-Pipeline-Review-H2-2016-2088-16258>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.